ESR1 and breast cancer: Label-free spectral counting and identification-based semi-quantitative shotgun proteomic analysis of microdissected target cancerous cells of a certain type, that characterized luminal B breast cancer tumors of ER+HER2− and Ki-67 score (> 80%), were used.